24.1 C
New York
HomeTop Global NewsBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal


Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing a $4.8 billion equity value.

Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.

The transaction is expected to be dilutive to Bristol-Myers Squibb’s non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.

Mirati stockholders will receive one non-tradeable Contingent Value Right for each Mirati share held, potentially worth $12.00 per share in cash.

The U.S. health regulator had in December approved Mirati’s lung cancer drug, Krazati, to treat adults with advanced lung cancer.



Source link

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here